ClinicalTrials.gov posted a newer version of NCT07487363, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
After
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]
We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
After
A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.
Evidence note
Before
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
After
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Status
Before
FDA identity record only; approval status not established
After
FDA compounding safety review; final determination pending
Status classification
Before
identity-only
After
safety-review
Topic
Before
Identity records
After
Safety records
Profile summary
Before
A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
After
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
Evidence note
Before
FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
After
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
Showing the latest 7 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: August 21, 2026.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
PeptideScanner retained PubMed bibliographic metadata for PMID 22962027 at 2026-07-30T16:30:49.822Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-09-11. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 23084823 at 2026-07-30T16:30:49.836Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-10-23. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 38382158 at 2026-07-30T18:48:13.580Z. PubMed recorded a metadata revision date of 2024-03-11 and an Entrez history date of 2024-02-21. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.